These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 467961)

  • 41. Reciprocal responses to clofibrate in ketogenesis and triglyceride and cholesterol secretion in isolated rat liver.
    Ide T; Oku H; Sugano M
    Metabolism; 1982 Oct; 31(10):1065-72. PubMed ID: 7132732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Preliminary study of the tolerance of 3-nicotinoyl-oxypropyl p-chlorophenoxy isobutyrate (I. 612) and on its effects on plasma lipid pattern, hemostasis and clotting-fibrinolysis balance].
    Buzzelli G; Doni A; Lippi G; Resina A
    Clin Ter; 1979 May; 89(3):251-66. PubMed ID: 466976
    [No Abstract]   [Full Text] [Related]  

  • 43. Influence of clofibrate on plasma lecithin: cholesterol acyltransferase (LCAT) activity in rats.
    Cisternas JR
    Rev Bras Pesqui Med Biol; 1979 Sep; 12(4-5):317-24. PubMed ID: 531275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Major clofibrate effects on liver and plasma lipids are independent of changes in polyunsaturated fatty acid composition induced by dietary fat.
    Pennacchiotti GL; Maldonado EN; Aveldaño MI
    Lipids; 2001 Feb; 36(2):121-7. PubMed ID: 11269691
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of tiadenol, clofibrate and clofibride on bile composition in the rat.
    Rozé C; Cuchet P; Souchard M; Vaille C; Debray C
    Eur J Pharmacol; 1977 May; 43(1):57-64. PubMed ID: 862664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters: its significance for the mechanism of lipid lowering by clofibrate and related drugs.
    Beaumont JL; Dachet C
    Atherosclerosis; 1976; 25(2-3):255-66. PubMed ID: 188431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. I. The effect of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in normal rats.
    Tomita T; Takeshita R; Nagakura T; Hayashi E
    Jpn J Pharmacol; 1973 Jun; 23(3):281-7. PubMed ID: 4541943
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of ethanol and clofibrate on the activity of lipid catabolism enzyme systems in rat liver].
    Antonenko VD; Popova SV; Panchenko LF
    Farmakol Toksikol; 1983; 46(5):86-90. PubMed ID: 6138280
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Biliary lipid composition during treatment with different hypolipidaemic drugs.
    Angelin B; Einarsson K; Leijd B
    Eur J Clin Invest; 1979 Jun; 9(3):185-90. PubMed ID: 113218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of clofibrate and of an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man.
    Pertsemlidis D; Panveliwalla D; Ahrens EH
    Gastroenterology; 1974 Apr; 66(4):565-73. PubMed ID: 4821079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does clofibrate mobilize cholesterol from tissues?
    Rothfeld B; Karmen A; Hunter CF; Varady A
    Biochem Med; 1971 Apr; 5(2):165-72. PubMed ID: 5131450
    [No Abstract]   [Full Text] [Related]  

  • 52. [Effect of clofibrate on lipoprotein-lipids in patients with type IV hyperlipoproteinaemia (author's transl)].
    Weisweiler P; Schwandt P
    Klin Wochenschr; 1977 Aug; 55(16):791-4. PubMed ID: 198601
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Field study on the decrease of lipids using etofibrate].
    Schneider J; Haase W; Kaffarnik H
    Fortschr Med; 1976 May; 94(13):785-90. PubMed ID: 8362
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Hyperlipoproteinemia].
    Meinders AE
    Ned Tijdschr Geneeskd; 1979 Mar; 123(15):617-28. PubMed ID: 219378
    [No Abstract]   [Full Text] [Related]  

  • 55. Newer hypolipidemic agents.
    Kritchevsky D
    Fed Proc; 1971; 30(3):835-40. PubMed ID: 4996475
    [No Abstract]   [Full Text] [Related]  

  • 56. Effects of clofibrate, cholestyramine, zanchol, probucol, and AOMA feeding on hepatic and intestinal cholesterol metabolism and on biliary lipid secretion in the rat.
    Turley SD; Dietschy JM
    J Cardiovasc Pharmacol; 1980; 2(3):281-97. PubMed ID: 6156326
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hypolipidemic effect of clofibrate and fatty acid oxidation in peroxisomes.
    Nutr Rev; 1977 Apr; 35(4):74-5. PubMed ID: 323754
    [No Abstract]   [Full Text] [Related]  

  • 58. Pharmacological study of hydroxy bis-[2-(p-chlorophenoxy)-isobutyric acid] aluminium. II. The effect of hydroxy bis-[2-(-chlorophenoxy)-isobutyric acid] aluminum on lipid metabolism in hypercholesterolimic rats.
    Tomita T; Yamamura Y; Nagakura T; Hayashi E
    Jpn J Pharmacol; 1973 Jun; 23(3):289-98. PubMed ID: 4353343
    [No Abstract]   [Full Text] [Related]  

  • 59. Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
    Spöttl F; Froschauer J
    Atherosclerosis; 1976; 25(2-3):293-301. PubMed ID: 1008913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The mechanism of action of lipid-lowering drugs.
    LaRosa JC
    Angiology; 1982 Sep; 33(9):562-76. PubMed ID: 7125296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.